NasdaqGS:IONSBiotechs
A Look At Ionis Pharmaceuticals (IONS) Valuation After FDA Priority Review Wins And Upgraded Revenue Guidance
Ionis Pharmaceuticals (IONS) has been in focus after a busy stretch that included US FDA Priority Review and Breakthrough Therapy designations for partner drug bepirovirsen, additional positive zilganersen data in Alexander disease, and a first quarter earnings update.
See our latest analysis for Ionis Pharmaceuticals.
The recent FDA designations for bepirovirsen, encouraging zilganersen data and raised 2026 revenue guidance help explain why Ionis Pharmaceuticals has a 1-year total...